...
首页> 外文期刊>Diabetes care >Optimal Glycemic Control, Pre-eclampsia, and Gestational Hypertension in Women With Type 1 Diabetes in the Diabetes and Pre-eclampsia Intervention Trial.
【24h】

Optimal Glycemic Control, Pre-eclampsia, and Gestational Hypertension in Women With Type 1 Diabetes in the Diabetes and Pre-eclampsia Intervention Trial.

机译:糖尿病患者1型糖尿病患者的最佳血糖对照,前异常血症和妊娠期高血压和先兆子痫干预试验。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE To assess the relationship between glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes. RESEARCH DESIGN AND METHODS Pregnancy outcome (pre-eclampsia or gestational hypertension) was assessed prospectively in 749 women from the randomized controlled Diabetes and Pre-eclampsia Intervention Trial (DAPIT). HbA(1c) (A1C) values were available up to 6 months before pregnancy (n = 542), at the first antenatal visit (median 9 weeks) (n = 721), at 26 weeks' gestation (n = 592), and at 34 weeks' gestation (n = 519) and were categorized as optimal (<6.1%: referent), good (6.1-6.9%), moderate (7.0-7.9%), and poor (>/=8.0%) glycemic control, respectively. RESULTS Pre-eclampsia and gestational hypertension developed in 17 and 11% of pregnancies, respectively. Women who developed pre-eclampsia had significantly higher A1C values before and during pregnancy compared with women who did not develop pre-eclampsia (P < 0.05, respectively). In early pregnancy, A1C >/=8.0% was associated with a significantly increased risk of pre-eclampsia (odds ratio 3.68 [95% CI 1.17-11.6]) compared with optimal control. At 26 weeks' gestation, A1C values >/=6.1% (good: 2.09 [1.03-4.21]; moderate: 3.20 [1.47-7.00]; and poor: 3.81 [1.30-11.1]) and at 34 weeks' gestation A1C values >/=7.0% (moderate: 3.27 [1.31-8.20] and poor: 8.01 [2.04-31.5]) significantly increased the risk of pre-eclampsia compared with optimal control. The adjusted odds ratios for pre-eclampsia for each 1% decrement in A1C before pregnancy, at the first antenatal visit, at 26 weeks' gestation, and at 34 weeks' gestation were 0.88 (0.75-1.03), 0.75 (0.64-0.88), 0.57 (0.42-0.78), and 0.47 (0.31-0.70), respectively. Glycemic control was not significantly associated with gestational hypertension. CONCLUSIONS Women who developed pre-eclampsia had significantly higher A1C values before and during pregnancy. These data suggest that optimal glycemic control both early and throughout pregnancy may reduce the risk of pre-eclampsia in women with type 1 diabetes.
机译:目的探讨血糖对照,前异常术前和患有1型糖尿病患者的妊娠期高血压的关系。研究设计和方法妊娠结局(预兴高采症或妊娠期高血压)在来自随机对照糖尿病和预普查先发产病患者的749名妇女中进行了评估,并在749名妇女中评估(Dapit)。 HBA(1C)(A1C)值最多可在怀孕前6个月(n = 542),在第一次出生访问(中位9周)(n = 721),在26周的妊娠(n = 592),在34周内妊娠(n = 519)并被分类为最佳(<6.1%:参考文献),良好(6.1-6.9%),中等(7.0-7.9%),差(> / = 8.0%)血糖控制, 分别。结果分别在17%至11%的怀孕中发育了前卵痫前和妊娠高血压。在未开发出预普利坦斯预痫(分别为P <0.05)之前,开发出预普利坦的妇女在怀孕之前和怀孕前的A1C值显着更高。在妊娠早期,与最佳对照相比,A1C> / = 8.0%与显着增加的预痫预质量增加(差异比例3.68 [95%CI 1.17-11.6])有关。在26周的妊娠,A1C值> / = 6.1%(好:2.09 [1.03-4.21];中等:3.20 [1.47-7.00];差:3.81 [1.30-11.1])和34周的妊娠A1C值> / = 7.0%(中等:3.27 [1.31-8.20]和差:8.01 [2.04-31.5])显着提高了与最佳控制相比预普利克敏的风险。在妊娠之前,在怀孕前,在妊娠第一次出现期间,在妊娠之前,在第一次出现妊娠期和34周内妊娠期妊娠期妊娠期妊娠期妊娠的调整后的差比为0.88(0.75-1.03),0.75(0.64-0.88) ,0.57(0.42-0.78)和0.47(0.31-0.70)。血糖控制与妊娠期高血压没有显着相关。结论开发出预普利克斯患者的妇女在怀孕之前和期间具有显着高的A1C值。这些数据表明,妊娠早期和整个妊娠早期的最佳血糖控制可能会降低患有1型糖尿病患者患者前异常普拉明裔的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号